Michael Keng headshot

Michael K. Keng

Associate Professor
Unit: School of Medicine
Department: Department of Medicine, Hematology and Oncology
Office location and address
Emily Couric Clinical Cancer Center
1335 Lee St
Charlottesville, Virginia 22903
Clinical Fellowship, Hematology-Oncology, Cleveland Clinic, Cleveland, Ohio
Residency, Internal Medicine, University of Southern California School of Medicine
MD, Michigan State University

Dr. Michael Keng holds a clinical faculty appointment in Medicine in the Division of Hematology/Oncology at UVA Cancer Center. He practices at the Emily Couric Clinical Cancer Center in Charlottesville and serves as an inpatient hematologist at UVA Hospital. His clinical areas of interest are: myelodysplastic syndromes, myeloproliferative disorders, acute myeloid leukemia, chronic myeloid leukemia, acute lymphoid leukemia, and aplastic anemia. He attended medical school at Michigan State University in East Lansing, Michigan and completed internal medicine residency at University of Southern California in Los Angeles, California. He completed fellowship in Hematology and Medical Oncology at the Cleveland Clinic, Cleveland, Ohio, in 2014, where he served as chief fellow from 2013-2014. Dr. Keng joined the University of Virginia in 2014. He lives with his wife and daughter and enjoys cooking, hiking, and travelling.

Clinical Testing of Ceramide NanoLiposome ("CNL") for Treatment of Acute Myeloid Leukemia
Source: Commonwealth Foundation for Cancer Research
June 01, 2020 – May 31, 2025
Source: Arog Pharmaceuticals LLC
June 14, 2019 – June 13, 2023
A Phase 1 Study of Ipilimumab in Combination with Decitabine in Relapsed or Refractory Myelodysplastic Syndrome/Acute Myeloid Leukemia6
Source: Johns Hopkins University, The
December 01, 2017 – February 28, 2023
MD-INMD-HO Keng - Biosight - BST002
Source: PRA Health Sciences
February 01, 2019 – January 31, 2023
MD-INMD-HO - Keng - Helsinn Healthcare SA - PRAN-16-52
Source: Clinipace, Inc.
May 22, 2018 – August 29, 2022
Keng Dana Farber 16-574
Source: Dana-Farber Cancer Institute, Inc.
May 30, 2018 – August 28, 2022
MD-INMD-HO Keng Millenium P-3001
Source: Millennium Pharmaceuticals, Inc.
August 22, 2018 – August 21, 2022
2-stage study of pracinostat + azacitidine in patients with high/very high risk MDS by R-IPSS who are candidate for azacitidine treatment
Source: MEI Pharma, Inc.
October 31, 2017 – June 28, 2022
MD-INMD-HO -Keng - Rafael UYA26495
Source: Rafael Pharmaceuticals, Inc.
April 18, 2019 – June 28, 2022
An Open Label Phase 2 Study of Itacitinib (INCB039110) in Combination with Low Dose Ruxolitinib or Itacitinib Alone Following Ruxolitinib in Subjects with Myelofibrosis
Source: Incyte Corporation
November 28, 2017 – November 27, 2020